Atlas Trials

Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy

Clinical trial NCT03422523 · TERMINATED

Trial details

NCT number
NCT03422523
Sponsor
University Hospital Southampton NHS Foundation Trust
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell LymphomaRelapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2018-05-09
Primary completion
2021-01-31
Enrollment
53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.